We evaluated the final height achieved by 47 patients who had bone marrow transplantation (BMT) for thalassemia major. Subjects were separated into two groups: patients who received BMT before 7 years of age and patients who received BMT after 7 years of age. Parental height and genetic target height (TH) were calculated. Our data indicated a strict correlation between age at time of transplant and final adult height. The patients whose age at transplant was Ͻ7 years had a less impaired growth rate than did patients who were Ͼ7 years. Moreover, greatest loss in height was observed in subjects who had higher serum levels of transaminase and ferritin and these biochemical parameters were strictly correlated to the final adult height. Mean final adult height, however, did not differ from the genetic target height in subjects who received BMT before 7 years of age and the final height SDS corrected for TH surpasses even the TH. In contrast, the subjects who received BMT after 7 years of age, failed to achieve their full genetic potential. In conclusion, short stature is present in a significant percentage of transplanted thalassemic children. The data in this study indicate a close effect of the age at time of transplant on subsequent growth rate, but the growth impairment in these subjects remain multifactorial. Bone Marrow Transplantation (2001) 28, 201-205. Keywords: bone marrow transplantation; thalassemia major; growth Growth retardation and delayed or absent development are frequently observed in patients with thalassemia major. Growth hormone deficiency is implicated as the cause in some patients, but other factors that could adversely influence growth have also been suggested. Bone marrow transplantation (BMT) following preparation with busulphan (BU) and cyclophosphamide (CY) can cure a high percentage of patients with compatible donors. Little is known about the long-term effects of BMT in patients with thalassemia in relation to the growth process as well as endocrine function. Several studies have considered growth and growth rate in thalassemic children after BMT, but the follow-up was short-term and the final height of these patients is not known.
about the long-term effects of BMT in patients with thalassemia in relation to the growth process as well as endocrine function. Several studies have considered growth and growth rate in thalassemic children after BMT, but the follow-up was short-term and the final height of these patients is not known.
In this study, we evaluated the final height achieved by patients who had bone marrow transplantation for thalassemia major.
Patients and methods
Of a cohort of 102 children transplanted for thalassemia major who received an allogeneic BMT from an HLA matched sibling, 47 subjects (28 male, 19 female) who have reached their final adult height, were studied. The criterion for final adult height was either at least 6 months without height gain or documented complete closure of the hand, wrist and iliac crest epiphyses. The mean age of the patients at BMT was 7.05 ± 2.81 years (range 3.11-12.7) and the mean age at the most recent follow-up examination was 20.57 ± 0.63 years (range 18.1-24.2).
Subjects were separated into two groups: group Apatients who received BMT before 7 years of age and group B -patients who received BMT after 7 years of age.
Prior to referral for BMT all patients were receiving desferrioxamine (DFX) administered by slow subcutaneous infusion by pump (40-50 mg/kg/day 6 night/week).
All had received multiple erythrocyte transfusions. The median number of transfusions was 135.2 ± 61.67 (range .
Transplant procedure
In preparation for marrow transplant, all patients received the BU-CY regimen. BU was given orally in four divided doses on each of 4 consecutive days (from days −9 to −6), followed by CY 50 mg/kg for 4 consecutive days (from days −5 to −2). The total dose of BU was 13 mg/kg in all patients.
Donor marrow was infused i.v. on day 0. All donors were genotypically HLA-identical and MLC-non-reactive siblings.
Graft-versus-host disease (GVHD) prophylaxis consisted either of cyclosporine A (CsA) alone or in combination with methotrexate. Details of the marrow grafting procedure and management of patients after grafting have been described elsewhere. 1 
Growth evaluation and blood analysis
Growth data were obtained from all patients at time of transplantation, 12 months before BMT, at 6 years after BMT and when final adult height was reached (Table 1) .
Height determinations were performed using a Harpenden stadiometer according to the criteria of Tanner. Height data were converted to standard deviation score (SDS) for the chronological age (hSDS). Complete closure of the hand, wrist and iliac crest epiphyses was estimated by a single observer from radiographs. Secondary sex characteristics development was evaluated by the Tanner and Whitehouse pubertal developmental standards for breast, pubic hair and genital maturity. Genetic target height (TH) was calculated from the average parental height plus 5.5 cm for the boys and minus 5.5 cm for the girls and these data were converted to SDS. Parental height SDS was also calculated. Finally, the SDS of the final adult height for each subject, corrected for TH, was also calculated.
Growth hormone (GH) secretion and IGF-1 levels were tested in all patients at 12 and 24 months after BMT. Routine blood and urine analyses were undertaken during the check-up. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were determined by standard methods. Serum ferritin levels were assessed by radioimmunoassay.
None of the patients had GVHD as graded according to the Seattle criteria. 4 All patients were tested for HCV-RNA both before BMT and during the follow-up. Liver biopsy was performed in only 13 patients. Grading systems were established to record siderosis, chronic aggressive hepatitis, chronic persistent hepatitis. Three grades of severity (mild, moderate and severe) were identified for each patient. Liver damage was moderate in eight and severe in five.
All had normal thyroid function.
Statistical analysis
Growth data are presented as SDS and as mean ± SD. Biochemical data were expressed as absolute single values and as means ± SD. Two-tailed Student's t-and Fisher's exact test and a simple linear regression analysis were performed to compare the data and to establish the significance level.
Results
None of the patients had GH deficiency as evaluated by a GH response Ͼ10 ng/ml to pharmacologic stimulation with insulin, arginine and/or clonidine.
In all patients the puberty started spontaneously. In boys the puberty started at the age of 13.6 ± 0.83 years (range Final adult heights SDS Figure 1 Final adult height SDS distribution in patients who underwent BMT before and after 7 years of age (group A and group B, respectively). The dotted area indicates the height SDS distribution for the normal population. The short lines indicate the median height SDS for each column.
13.1-14.7)
. In girls the menarche occurred at 13.45 ± 0.86 years (range 12.1-15.0). Single values of the final adult height of patients, expressed as a standard deviation score, are given in Figure 1 . Figure 2 shows the outcome of the hSDS for patients who received their BMT before and after 7 years of age, respectively. Growth was constant over time for the younger patients whereas the older patients had a significant increase in growth delay at final adult height compared to hSDS at the time of BMT, evaluated with the two-tailed Student's t-test (P = 0.004). Moreover, 18 of 26 younger patients (BMT Ͻ7 years) showed an improvement in their growth delay compared to five of 21 older patients (P = 0.001 evaluated with the Fisher's exact test).
Despite the general trend towards decrease in hSDS found after BMT, in group B only 9/21 (42.8%) patients reached a pathological SDS value of below −2. These subjects had serum transaminase and ferritin levels higher than did the other patients.
A good correlation (r = −0.792, P = 0.00001, SEE 0.54) 
Figure 3
Linear regression and correlation between the age at BMT and hSDS evaluated at final adult height.
was found between age at BMT and hSDS evaluated at final adult height ( Figure 3 ). Good correlations were also found between hSDS and ferritin, AST and ALT in group B (r = −0.672, P = 0.0008, SEE 0.57; r = −0.727, P = 0.0002, SEE 0.53; r = −0.511, P = 0.01, SEE 0.66, respectively) but not in group A (r = 0.182; r = −0.223 and r = 0.020, P NS) ( Groups A and B: patients who received BMT before and after 7 years of age, respectively. BMT = bone marrow transplantation; hSDS = height standard deviation score; NS = P not significant. 
Correlation between final adult height SDS and parental height
The height of both parents was available by direct measurements in all cases. Mean values of parents' hSDS were: −0.73 ± 0.76 (range −2.4 to 0.9) for mothers and −0.03 ± 0.91 (range −2.1 to 1.4) for fathers. The 4.25% (2/47) of fathers and the 6.38% (3/47) of mothers were smaller than the 3rd percentile. The correlation between final adult height SDS and parental height is presented in Table 3 .
Analyzing the two groups separately, a good positive correlation was found in group A between final adult height SDS and mothers' height (r = 0.661, P = 0.0003, SEE 0.41), fathers' height (r = 0.690, P = 0.0001, SEE 0.39) and TH (r = 0.429, P = 0.02, SEE 0.48) respectively. In this group the final adult height SDS, corrected for TH, exceded even the TH (0.49 ± 0.62 vs 0.05 ± 0.78, P = 0.01). In contrast, group B showed no relation with either parental height and TH (r = −0.060; r = −0.130 and r = −0.121, respectively). Moreover, in this group there was a worsening of the final adult height SDS, corrected for TH, with respect to the TH (−0.79 ± −0.73 vs −0.42 ± 0.74, P = 0.05); in fact all patients failed to achieve their full genetic potential. 
Discussion
In recent years several studies have documented that short stature is a common observation in children with thalassemia major treated with conventional therapy of transfusion and chelation. The increasing number of long-term survivors after bone marrow transplantation has focused attention on the impaired growth of these patients. Many factors have been implicated in the growth retardation: deranged function of the hypothalamic-pituitary-gonadal axis, [5] [6] [7] [8] [9] [10] [11] abnormal hepatic conversion of steroid hormones to their active metabolites 12 and defective hepatic biosynthesis of insulin like growth factor (IGF-I). 13 It is possible that iron overload is primarily involved in this phenomenon. Chronically transfused, inadequately chelated patients develop hepatocellular injury and late growth failure within the first decade of life. This is followed in adolescence by pubertal failure and dysfunction of various endocrine organs.
Allogeneic BMT represents the only definitive cure for patients with thalassemia major but that is available only if there is an HLA-identical sibling donor. 1, 14, 15 In order to eradicate the underlying hematological disorder and to suppress the patient's immune system, all patients receive high doses of BU and CY. It is of interest to ascertain the late effects of this treatment modality on the child's subsequent growth as well as the possible benefits of eliminating transfusion therapy.
Discordant data concerning GH secretion in thalassemic patients are present in literature. Some studies indicate that patients treated with conventional therapy have normal GH secretion after pharmacological stimuli, 5, 6, [16] [17] [18] while others indicate either reduced GH secretion following stimulation with GHRH [19] [20] [21] or reduced spontaneous GH secretion all day with a low number of pulses and reduced mean pulse amplitude. 22 In short-stature patients with a normal GH response to provocative stimulation tests, abnormal pulsatile GH secretion has been reported (neurosecretory dysfunction). 23 However, definite data about GH secretion in transplanted thalassemic patients are lacking in the literature. 24 Many studies dealing with the growth of these patients who have undergone bone marrow transplantation report only limited data for the first few years after transplantation. 24, 25 In this study we analyzed the final height achieved by a population of patients with thalassaemia major who underwent allogeneic bone marrow transplantation during childhood. None of the patients had GH deficiency. Moreover, there was no evidence of malnutrition or other endocrine disfunction that may have affected growth in these patients.
In this study we found that short stature (below −2DS) is present approximatively in 17% of our subjects. Severe growth delay (below −3DS) was observed only in the 6.3%.
Our data also indicate a strict correlation between age at time of transplant and final adult height. The patients whose age at transplant was Ͻ7 years had a less impaired growth rate than did patients who were Ͼ7 years. We found a similar finding in a previous study performed on 22 other patients 48 months after bone marrow transplantation. 24 Mean final adult height, however, did not differ from the genetic target height in subjects who received BMT before 7 years of age and the final height SDS corrected for TH exceded even the TH. In contrast, the subjects who received BMT after 7 years of age failed to achieve their full genetic potential.
These results may be explained by the possible decreased bioavailability of BU noted in very young children (age Ͻ6-7 years) imposing thereby a reduced toxic effect on the endocrine system. Furthermore, the busulfan may have been metabolized differently in the older than the younger patients due to impaired hepatic function secondary to both iron overload and inflammatory changes. In fact, greatest loss in height was observed in subjects who had higher serum levels of transaminase and ferritin and these biochemical parameters were strictly correlated with the final adult height.
Our previous data also demonstrated that liver damage plays a major role in causing the growth disorder because of an abnormal biosynthesis of IGF-I. 24 This pattern of correlation suggests that the duration of the disease before BMT may be an important factor regarding the defect in IGF-I production related to liver damage.
Other causes of incomplete normalization of final height may depend on the negative role played by DFX therapy. An early start of daily chelation has been correlated with growth impairment. 26 Cavallo et al 27 found that a late start in chelation therapy has a negative, yet minor effect, on growth and bone maturation. More recently, typical bone lesions associated with growth failure, due to DFX toxicity, have been observed in thalassemic patients. [28] [29] [30] Furthermore, several reports indicate that toxic effects of DFX may be responsible for the short trunk and skeletal lesions, 28, 29, 31 but we did not study this association.
As regards preparative regimen it seems that CY alone rarely affects endocrine function. However, little is known about the effects of chemotherapy regimens including BU and CY. In a report about children receiving BMT for leukemia, growth impairment was comparable for patients who received BU-CY or, as an alternative, CY/total body irradiation. 32 Other known causes of growth impairment in patients receiving allogeneic BMT cannot be evaluated; no patient in either group suffered from chronic GVHD or received prolonged treatment with steroids.
In conclusion, short stature is present in a significant percentage of transplanted thalassemic children. The data in this study indicate a close effect of age at time of transplant on subsequent growth rate, but the growth impairment in these subjects remains the result of various factors.
